MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls.
Cristina M GaudiosoSoe S MarT Charles CasperRachel CoddenAdam NguyenGregory AaenLeslie BensonTanuja ChitinisCarla FranciscoMark P GormanManu S GoyalJennifer S GravesBenjamin M GreenbergJanace HartLauren KruppTimothy LotzeSona NarulaSean J PittockMary RenselMoses RodriguezJohn RoseTeri SchreinerJan-Mendelt TillemaAmy WaldmanBianca Weinstock-GuttmanYolanda WheelerEmmanuelle WaubantEoin P Flanagannull nullPublished in: Annals of neurology (2022)
MOG-IgG and AQP4-IgG were not identified among healthy controls confirming their high specificity for pediatric central nervous system (CNS) demyelinating disease. Five percent of those with prior POMS diagnoses ultimately had MOGAD; and none had AQP4-IgG positivity. Clinical features associated with a final diagnosis of MOGAD in those with suspected MS included initial ADEM phenotype, younger age at disease onset, and lack of EBV exposure. ANN NEUROL 2022.